Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

• Published in: Journal of the American Academy of Dermatology Vol. 73; no. 4; pp. 594 - 603
• Main Authors: Landells, Ian, MD, FRCPC, Marano, Colleen, PhD, Hsu, Ming-Chun, PhD, Li, Shu, PhD, Zhu, Yaowei, PhD, Eichenfield, Lawrence F., MD, Hoeger, Peter H., MD, Menter, Alan, MD, Paller, Amy S., MS, MD, Taieb, Alain, MD, Philipp, Sandra, MD, Szapary, Philippe, MD, MSCE, Randazzo, Bruce, MD, PhD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-10-2015
• Subjects: Adolescent; Age Factors; Antibodies, Monoclonal - administration & dosage; biologic; Child; children; Dermatology; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Male; pediatric; psoriasis; Psoriasis - diagnosis; Psoriasis - drug therapy; Risk Assessment; Severity of Illness Index; systemic therapy; Treatment Outcome; ustekinumab; Ustekinumab - administration & dosage; PASI 90; PGA of cleared or minimal; PASI 75; Children's Dermatology Life Quality Index; half-standard dose; at least 75% improvement in PASI; Psoriasis Area and Severity Index; pediatric; SD; ustekinumab; children; serious adverse event; HSD; at least 90% improvement in PASI; HRQoL; standard dose; Physician's Global Assessment; PGA 0/1; PASI; AE; biologic; adverse event; health-related quality of life; PGA; systemic therapy; CDLQI; psoriasis; SAE; adolescent
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2015.07.002

Background Safe and effective therapies are needed for pediatric patients with psoriasis. Objective The purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had moderate-to-severe psoriasis. Methods Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg [≤60 kg], 45 mg [>60-≤100 kg], and 90 mg [>100 kg]) or half-standard dosing (HSD; 0.375 mg/kg [≤60 kg], 22.5 mg [>60-≤100 kg], and 45 mg [>100 kg]) at weeks 0 and 4 and every 12 weeks or placebo at weeks 0 and 4 with crossover to ustekinumab SD or HSD at week 12. Clinical assessments included the proportion of patients achieving a Physician's Global Assessment of cleared/minimal (PGA 0/1), at least 75% improvement in Psoriasis Area and Severity Index (PASI 75), and at least 90% in PASI (PASI 90). Adverse events (AEs) were monitored through week 60. Results At week 12, 67.6% and 69.4% of patients receiving ustekinumab HSD and SD, respectively, achieved PGA 0/1 versus 5.4% for placebo ( P  < .001). Significantly greater proportions receiving ustekinumab achieved PASI 75 (HSD, 78.4%; SD, 80.6%; placebo, 10.8%) or PASI 90 (HSD, 54.1%; SD, 61.1%; placebo, 5.4%) at week 12 ( P  < .001). Through week 12, 56.8% of placebo patients, 51.4% of HSD patients, and 44.4% of SD patients reported at least one AE; through week 60, 81.8% reported AEs. Limitations The study was small relative to adult trials. Conclusions In this patient population (12–17 years), the standard ustekinumab dose provided response comparable to that in adults with no unexpected AEs through 1 year.